Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Tesamorelin + Ipamorelin Blend Enhanced GH Release Results Timeline Expect: Full Comparison

The table below contrasts the tesamorelin + ipamorelin blend timeline against single-agent protocols and exogenous recombinant GH. Tesamorelin + Ipamorelin Blend 8–15 (60–90 min post-injection) Week 2–3 (15–25% above baseline) 1.4–2.1 kg Week 4–6 (subcutaneous

This comparison does not assign a generated winner or score.

  • The table below contrasts the tesamorelin + ipamorelin blend timeline against single-agent protocols and exogenous recombinant GH.
  • Tesamorelin + Ipamorelin Blend
  • 8–15 (60–90 min post-injection)
  • Week 2–3 (15–25% above baseline)
  • 1.4–2.1 kg
  • Week 4–6 (subcutaneous fat reduction)
  • Dual-pathway stimulation produces higher peak GH and faster IGF-1 response than single agents. Ideal for time-sensitive research protocols requiring measurable tissue effects within 8–12 weeks
  • Tesamorelin Monotherapy
  • 5–9 (90–120 min post-injection)
  • Week 3–4 (12–18% above baseline)
  • 1.0–1.4 kg
  • Week 6–8
  • GHRH analog alone produces moderate GH elevation. Adequate for long-term metabolic studies but slower tissue response than combined protocols
  • Ipamorelin Monotherapy
  • 4–7 (60 min post-injection)
  • Week 4–5 (10–15% above baseline)
  • 0.8–1.2 kg
  • Week 8–10
  • Secretagogue-only protocols lack the GH synthesis upregulation that GHRH provides. Lower peak GH and delayed IGF-1 rise limit short-term tissue outcomes
  • Recombinant GH (Exogenous)
  • Continuous elevation (5–12 ng/mL)
  • Immediate (IGF-1 rises within 48–72 hours)
  • 2.0–3.5 kg
  • Week 2–4
  • Exogenous GH bypasses endogenous regulation entirely. Faster tissue effects but higher receptor downregulation risk and no preservation of natural pulsatile secretion
  • MK-677 (Oral Ghrelin Mimetic)
  • 3–6 (sustained elevation 12–24 hours)
  • Week 3–4 (10–18% above baseline)
  • 1.2–1.8 kg
  • Oral bioavailability and sustained GH elevation avoid injection protocols, but ghrelin pathway cross-reactivity causes appetite stimulation and water retention in 40–50% of subjects
More references

Related material